Zacks: Myomo, Inc. (NASDAQ:MYO) Given $3.38 Average Target Price by Analysts

Shares of Myomo, Inc. (NASDAQ:MYO) have been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Brokerages have set a twelve-month consensus price target of $3.38 for the company and are predicting that the company will post ($0.17) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Myomo an industry rank of 75 out of 256 based on the ratings given to related companies.

MYO traded down $0.05 during midday trading on Monday, hitting $0.72. 49,500 shares of the company were exchanged, compared to its average volume of 83,048. The business has a 50 day moving average of $0.79. Myomo has a 1-year low of $0.66 and a 1-year high of $2.69.

Myomo (NASDAQ:MYO) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.03. The company had revenue of $0.83 million for the quarter, compared to analyst estimates of $0.86 million.

Myomo Company Profile

Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.

Featured Article: Buyback

Get a free copy of the Zacks research report on Myomo (MYO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with's FREE daily email newsletter.